SG11201605883UA - Compositions for use in the treatment of allergic conditions - Google Patents

Compositions for use in the treatment of allergic conditions

Info

Publication number
SG11201605883UA
SG11201605883UA SG11201605883UA SG11201605883UA SG11201605883UA SG 11201605883U A SG11201605883U A SG 11201605883UA SG 11201605883U A SG11201605883U A SG 11201605883UA SG 11201605883U A SG11201605883U A SG 11201605883UA SG 11201605883U A SG11201605883U A SG 11201605883UA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
use
allergic conditions
allergic
Prior art date
Application number
SG11201605883UA
Inventor
Steven G Reed
Christopher H Clegg
Christopher Arendt
Alexandra Kropotova
Kurt Stoeckli
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201461929780P priority Critical
Application filed by Immune Design Corp filed Critical Immune Design Corp
Priority to PCT/US2015/012003 priority patent/WO2015112485A1/en
Publication of SG11201605883UA publication Critical patent/SG11201605883UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
SG11201605883UA 2014-01-21 2015-01-20 Compositions for use in the treatment of allergic conditions SG11201605883UA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201461929780P true 2014-01-21 2014-01-21
PCT/US2015/012003 WO2015112485A1 (en) 2014-01-21 2015-01-20 Compositions for use in the treatment of allergic conditions

Publications (1)

Publication Number Publication Date
SG11201605883UA true SG11201605883UA (en) 2016-08-30

Family

ID=52462439

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605883UA SG11201605883UA (en) 2014-01-21 2015-01-20 Compositions for use in the treatment of allergic conditions

Country Status (17)

Country Link
US (1) US20160030459A1 (en)
EP (1) EP3096764A1 (en)
JP (1) JP2017502977A (en)
KR (1) KR20160105813A (en)
CN (1) CN105960241A (en)
AU (1) AU2015209575A1 (en)
CA (1) CA2935722A1 (en)
CL (1) CL2016001843A1 (en)
CR (1) CR20160369A (en)
EA (1) EA201691452A1 (en)
IL (1) IL246587D0 (en)
MA (1) MA39228A1 (en)
MX (1) MX2016009464A (en)
PH (1) PH12016501434A1 (en)
SG (1) SG11201605883UA (en)
TW (1) TW201620524A (en)
WO (1) WO2015112485A1 (en)

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122B1 (en) 1969-04-01 1982-11-23
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5352449A (en) 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (en) 1989-07-03 1991-10-25 Seppic Sa Vaccines and fluids active principles of vectors containing a metabolizable oil
FR2649012B1 (en) 1989-07-03 1991-10-25 Seppic Sa injecting multiphase emulsions
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
AU4662393A (en) 1992-07-08 1994-01-31 Schering Corporation Use of gm-csf as a vaccine adjuvant
DE69434745T2 (en) 1993-11-02 2006-10-05 Matsushita Electric Industrial Co., Ltd., Kadoma Method for producing an aggregate of micro-needles made of semiconductor material and method for producing a semiconductor component with such an aggregate
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE9319879U1 (en) 1993-12-23 1994-03-17 Inventa Ag Sequentially coextruded coolant line
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2201551T3 (en) 1997-09-05 2004-03-16 Glaxosmithkline Biologicals S.A. Oil in water emulsions containing saponins.
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6685699B1 (en) 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
JP4162813B2 (en) 1999-10-28 2008-10-08 久光製薬株式会社 Iontophoresis device
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
AT555808T (en) * 2006-09-26 2012-05-15 Infectious Disease Res Inst Vaccine composition with a synthetic adjuvans
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA2698668A1 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
CA2764374A1 (en) * 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants

Also Published As

Publication number Publication date
KR20160105813A (en) 2016-09-07
CN105960241A (en) 2016-09-21
AU2015209575A1 (en) 2016-07-21
CR20160369A (en) 2016-10-05
WO2015112485A1 (en) 2015-07-30
US20160030459A1 (en) 2016-02-04
CA2935722A1 (en) 2015-07-30
PH12016501434A1 (en) 2016-09-14
MX2016009464A (en) 2017-01-16
EA201691452A1 (en) 2016-12-30
MA39228A1 (en) 2017-06-30
JP2017502977A (en) 2017-01-26
TW201620524A (en) 2016-06-16
IL246587D0 (en) 2016-08-31
CL2016001843A1 (en) 2017-04-28
EP3096764A1 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
SG11201607705XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
IL248143D0 (en) Methods and compositions for immunomodulation
IL246833D0 (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PL3157512T3 (en) Use of cannabidiol in the treatment of epilepsy
GB201411197D0 (en) Composition and use thereof
IL249011D0 (en) Methods and compositions relating to exosomes
IL260257D0 (en) Compositions and methods for the treatment of hemoglobinopathies
BR112018001190A2 (en) compositions useful for treating kit and pdfgr-related disorders
RU2018110379A (en) Compounds and compositions used for the treatment of ntrk disorders
IL259576D0 (en) Compositions and methods for immunooncology
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
ZA201705060B (en) Use of picolinamides as fungicides
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
IL251529D0 (en) Use of cannabinoids in the treatment of epilepsy
IL251566D0 (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
IL251724D0 (en) Compositions and methods for the treatment of meibomian gland dysfunction
AP201709771A0 (en) Carrier-antibody compositions and methods of making and using the same
HK1232147A1 (en) Cenicriviroc for the treatment of fibrosis
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
EP3102200A4 (en) Therapeutic compounds and compositions
HK1222398A1 (en) Compositions and methods for the treatment of burkholderia infections
IL248519D0 (en) Bioceramic compositions and biomodulatory uses thereof
EP3379935A4 (en) Methods and compositions for reducing vancomycin-resistantenterococci
GB201510664D0 (en) Use of cannabinoids in the treatment of epilepsy
IL251526D0 (en) Use of cannabidiol in the treatment of tuberous sclerosis complex